Biotech Stock Harrow Crumbles After Its Most-Watched Product Misses | Investor's Business DailyBREAKING: Futures Fall; Broadcom Jumps Late---Top-notch biotech stock Harrow (HROW) crumbled Tuesday after its most-watched product, an eye drop called Vevye, missed Wall Street's fourth-quarter sales expectations.Vevye is a preservative- and water-free eye drop used twice a day to treat dry eye disease. December-quarter sales jumped more than 62% to $25.9 million. But that missed forecasts ranging from $29.96 mil ...